1Grabrlck DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer, JAMA. 2000;284:1791-1798.
2Collaborative Group on Hormonal Factors In Breast Cancer, Breast cancer and homronal contraceptives: collaborative reanalysis of Indivldual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemlological studies Lancet 1996:347:1713-1727
3Tulinlus H.Sigvaldson H.Olafsdottir G.Tyrggvadottir L.Bjarmadottir K.Breast cancer Incidence and famillallty in lceland during 75 years from 1921 to 1995 J Med Canet 1999;36:103-107.
4Claus EB,Risch N.Thomposon WB.Autosomal dominant inheritance of early onset breast cancer:Implications for risk perdiction Cancer.1994.73:643-651.
5Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemological studies of 52.705 women with breast cancer and 108.411 women without breast cancer Lancet.1997.350:1047-1059.
6Fisher B.Costantion JP.Wickerham L.et al.Tamoxifen for the prevention of breat cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst.1998.90:1371-1388.
7Cummings SR.Eokert S.Kreguer KA.et al.The effect of raloxifene on risk of breast cancer in post-menopausal women:resufts from the MORE randomized trial JAMA.1999.281:2189-2197.
8Whittemora AS.Harris R.Itnyre J and the Collaborative Ovarian Cancer group.Characteristics relating to ovarian cancer risk:collaborative analysis of 12 US case control studies II:Invasive epithellal ovarlan cancers in white women Am J Epidemiol 1992.136.1184-1203.
9Franceschi S.Parazzini F.Negrl E.et al.Pooled analysis of 3 European case control studies of epithellal ovarian cancer Ⅲ:oral contraceptive use,Int J Cancer 1991.49:61-65.
10Narod SA.Risch H.Moslehi R.et al.Oral contraceptives and the risk of hereditary ovarian cancer N Engl J Med.1998.339:424-428.
